2016 – Zydus received approval from the USFDA to initiate Phase II clinical trials of saroglitazar in patients with Non-Alcoholic Steatohepatitis (NASH) of the liver in the US
Press ESC key to close search
This information is intended for Healthcare Professionals in Sri Lanka only
